credit: social media

It said on Thursday that it will pay $3.7 billion to acquire ChemoCentryx Inc.....

credit: social media

as the American pharmaceutical company looks to expand its portfolio with a recently.....

credit: social media

licensed potential blockbuster anti-inflammation medicine.....

credit: social media

ChemoCentryx shares, which as of last close were down almost 34% for the year.....

credit: social media

more than quadrupled in value to trade at $51.40 before the bell.....

credit: social media

By adding Tavneos from ChemoCentryx, which last year received FDA clearance.....

credit: social media

for a rare immune-system disorder, the purchase, which is expected to be finalized by.....

credit: social media

the end of the year strengthens Amgen's pipeline of cancer and immune treatments......

credit: social media

ChemoCentryx shares were soaring at $50.45 in premarket trade on Thursday, up around 109 percent.

More Trending Stories Here